Compare Dover Corp (DOV) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs BIO-TECHNE Corp — how do they compare? Dover Corp trades at $189.1 (market cap $25.45B), while BIO-TECHNE Corp trades at $72.45 (market cap $11.36B). The key difference: Dover Corp is far larger — about 2.2× BIO-TECHNE Corp's market cap, and Dover Corp pays the higher dividend (1.11%). Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and BIO-TECHNE Corp for 63 Days on average.
| DOV | TECH | |
|---|---|---|
Market Cap | $25.45B | $11.36B |
Volume | 661,758 | 5,390,331 |
Sector | Industrials | Health |
52-Week High | $233.31 | $72.61 |
52-Week Low | $161.16 | $43.31 |
Typical Hold Time | 73 Days | 63 Days |
Enterprise Value | $26.95B | $11.39B |
Dividend Yield | 1.11% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $188.29, down 1.87% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and healthy profitability (13.48% net margin, 14.98% ROE). Recent acquisitions of Cloeren and Leistung expand manufacturing capabilities, while analyst consensus remains strongly bullish with a $243.20 price target representing 29% upside potential.
The outlook remains positive given Dover's Dividend King status, strategic acquisitions, and Wall Street support. Key risks include cyclical industrial exposure and recent negative cash flow trends. With no analyst sell ratings and technical indicators suggesting potential oversold conditions, the stock presents a compelling opportunity for long-term investors despite near-term bearish technical signals.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
